Skip Navigation
Search Menu

Print This Page
Share this page: More

Search Results

E2810 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Protocol Number:
Phase III
Hans-Joerg Hammers
Johns Hopkins Kimmel Cancer Center in Baltimore
This research is being done to determine whether taking an oral drug known as pazopanib (Votrient®) will reduce the risk of the cancer recurring in the future.
Generally healthy adults with renal cell carcinoma may be eligible to participate if you: Have no evidence of disease after surgery, Have not received prior chemotherapy, Have normal laboratory results and blood pressure, Have normal ECG results, and Are not pregnant or nursing.
Eligible subjects will receive either pazopanib by mouth each day or a matching placebo (an inactive substance that looks like the study drug, but contains no medication). You will be randomly assigned, like flipping a coin, to either regimen. You or your doctor will not be able to choose the regimen. You will continue to take your assigned study drug for about 1 year. You will have imaging done every 3 months to monitor your disease.
Last Update
02/09/2016 05:01 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.